← All trials
NCT04418089
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 15, 2018
- Primary completion
- May 20, 2019
- Completion date
- Sep 5, 2019
- First posted
- Jun 5, 2020
- Last posted
- Jun 5, 2020
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of IndonesiaLead sponsor
- University of IndonesiaReponsible party - principal investigator
- Faculty of Medicine Universitas Indonesia - Dr Cipto Mangunkusumo HospitalStudy chair
- Faculty of Medicine Universitas Indonesia - Dr Cipto Mangunkusumo HospitalStudy chair
- Department of Surgery, Koja General Hospital, Jakarta, IndonesiaStudy chair
- Faculty of Medicine Universitas Indonesia - Dr Cipto Mangunkusumo HospitalStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.